Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedApr 01, 2026
DataAggregated Company Financials
Companies62
  • 7D0.3%
  • 3M-17.1%
  • 1Y-1.3%
  • YTD-18.2%

Over the last 7 days, the Life Sciences industry has remained flat, although notably Tempus AI declined by 7.4%. Furthermore, the industry has been flat for the past year as well. Earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Apr 2026US$540.2bUS$147.8bUS$14.1b36.6x38.4x3.7x
Fri, 27 Feb 2026US$591.1bUS$147.9bUS$14.0b34.9x42.2x4x
Sun, 25 Jan 2026US$693.6bUS$145.8bUS$12.4b36x56.1x4.8x
Tue, 23 Dec 2025US$651.7bUS$145.8bUS$12.5b35.2x52.2x4.5x
Thu, 20 Nov 2025US$648.1bUS$145.7bUS$12.2b34x53.2x4.4x
Sat, 18 Oct 2025US$628.7bUS$144.3bUS$14.6b33x43.2x4.4x
Mon, 15 Sep 2025US$565.3bUS$144.3bUS$14.6b28.6x38.8x3.9x
Wed, 13 Aug 2025US$550.7bUS$144.1bUS$14.4b29.7x38.3x3.8x
Fri, 11 Jul 2025US$541.8bUS$142.9bUS$9.1b37.2x59.3x3.8x
Sun, 08 Jun 2025US$518.0bUS$142.9bUS$9.2b35.6x56.5x3.6x
Tue, 06 May 2025US$524.0bUS$142.4bUS$9.7b37.5x54.3x3.7x
Thu, 03 Apr 2025US$558.3bUS$142.5bUS$10.0b37.6x55.9x3.9x
Sat, 01 Mar 2025US$599.5bUS$143.3bUS$9.7b38.1x61.7x4.2x
Mon, 27 Jan 2025US$700.4bUS$142.4bUS$10.2b45.1x68.6x4.9x
Wed, 25 Dec 2024US$658.4bUS$142.4bUS$10.2b44.7x64.4x4.6x
Fri, 22 Nov 2024US$644.5bUS$142.4bUS$10.4b43.8x62.2x4.5x
Sun, 20 Oct 2024US$736.4bUS$141.8bUS$8.5b37.2x86.7x5.2x
Tue, 17 Sep 2024US$740.7bUS$141.8bUS$8.5b37.7x87.1x5.2x
Thu, 15 Aug 2024US$733.6bUS$141.5bUS$8.4b38.6x87.8x5.2x
Sat, 13 Jul 2024US$681.6bUS$141.2bUS$12.2b40.7x55.8x4.8x
Mon, 10 Jun 2024US$713.3bUS$141.3bUS$12.2b37.7x58.6x5x
Wed, 08 May 2024US$715.6bUS$141.6bUS$12.5b39.8x57.4x5.1x
Fri, 05 Apr 2024US$727.9bUS$142.1bUS$12.8b42.7x56.9x5.1x
Sun, 03 Mar 2024US$744.0bUS$142.2bUS$12.8b44.2x58.1x5.2x
Tue, 30 Jan 2024US$698.4bUS$153.8bUS$14.2b36x49.3x4.5x
Thu, 28 Dec 2023US$704.7bUS$153.8bUS$14.2b37.9x49.5x4.6x
Sat, 25 Nov 2023US$642.8bUS$153.8bUS$14.0b34.7x45.9x4.2x
Mon, 23 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Wed, 20 Sep 2023US$688.0bUS$154.6bUS$11.2b32.3x61.4x4.5x
Fri, 18 Aug 2023US$708.0bUS$154.6bUS$11.2b32.5x63.2x4.6x
Sun, 16 Jul 2023US$706.2bUS$155.5bUS$12.7b29.3x55.7x4.5x
Tue, 13 Jun 2023US$692.4bUS$152.4bUS$12.5b29.3x55.4x4.5x
Thu, 11 May 2023US$685.9bUS$152.3bUS$12.7b30x53.9x4.5x
Sat, 08 Apr 2023US$720.1bUS$154.6bUS$10.8b26.7x66.7x4.7x
Price to Earnings Ratio

66.7x


Total Market Cap: US$720.1bTotal Earnings: US$10.8bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 57.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.4x which is lower than its 3-year average PE of 57.7x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 9.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.61%
Healthcare1.34%
Life Sciences0.33%
Clinical Research and Equipment0.33%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IQV IQVIA HoldingsUS$170.542.7%
+US$747.0m		-0.4%PE21x
ICLR ICONUS$110.669.3%
+US$716.3m		-33.6%PE14.1x
CRL Charles River Laboratories InternationalUS$172.508.4%
+US$655.2m		18.2%PS2.1x
MEDP Medpace HoldingsUS$480.194.2%
+US$552.0m		61.3%PE30.2x
TMO Thermo Fisher ScientificUS$491.530.3%
+US$460.6m		1.8%PE27.2x

Latest News

TMO
US$491.53
Thermo Fisher Scientific
7D
0.3%
1Y
1.8%
CRL
US$172.50
Charles River Laboratories International
7D
8.4%
1Y
18.2%
MEDP
US$480.19
Medpace Holdings
7D
4.2%
1Y
61.3%
ILMN
US$123.26
Illumina
7D
-2.2%
1Y
57.2%
BIO
US$278.75
Bio-Rad Laboratories
7D
2.4%
1Y
16.1%
DHR
US$189.60
Danaher
7D
-0.3%
1Y
-5.4%
MTD
US$1,261.20
Mettler-Toledo International
7D
-0.3%
1Y
9.1%

MTD: Ongoing Share Buybacks And 2026 Sales Outlook Will Support Upside Potential

Analysts have nudged their price target for Mettler-Toledo International slightly higher to $1,505 from $1,501, reflecting small adjustments to fair value, discount rate, revenue growth assumptions, profit margin expectations, and future P/E estimates. What's in the News Mettler-Toledo International repurchased 104,192 shares between October 1, 2025 and December 31, 2025, representing 0.51% of its shares for US$143.75 million under its ongoing buyback program.
A
US$113.98
Agilent Technologies
7D
-0.2%
1Y
-0.06%

A: New Diagnostic Approval Will Drive Upside For Long Term Outlook

Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).
TEM
US$45.22
Tempus AI
7D
-7.4%
1Y
-4.2%

TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution

Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.
STVN
US$13.75
Stevanato Group
7D
-4.1%
1Y
-34.1%

STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows

Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.
ICLR
US$110.66
ICON
7D
9.3%
1Y
-33.6%
TXG
US$21.23
10x Genomics
7D
7.2%
1Y
144.9%

TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup

Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.
WAT
US$297.80
Waters
7D
-1.4%
1Y
-16.3%

WAT: New Four Division Model Will Support Higher Long Term Profitability

Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.
PSNL
US$6.37
Personalis
7D
-18.1%
1Y
84.6%

PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward

Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.
IQV
US$170.54
IQVIA Holdings
7D
2.7%
1Y
-0.4%

IQV: Future Returns Will Lean On AI Efficiencies In Clinical Trials

The updated analyst price target for IQVIA Holdings moves to $200 from $186.40 as analysts factor in slightly higher revenue growth, modestly stronger profit margins, and a higher assumed future P/E multiple supported by recent upgrades that highlight AI efficiencies and expected clinical trial activity. Analyst Commentary Recent Street research around IQVIA reflects a mix of renewed optimism and lingering caution.
WST
US$250.64
West Pharmaceutical Services
7D
2.2%
1Y
13.8%